Interinstitutional Center of Neurological Medicine, IRCCS National Neurological Institute C. Mondino Foundation, Pavia, Italy.
Department of Brain and Behaviour, University of Pavia, Pavia, Italy.
Pharmacology. 2019;104(1-2):1-6. doi: 10.1159/000499371. Epub 2019 Apr 3.
To assess the effects of chronic evening oral administration of bromazepam alone or in combination with propranolol on ambulatory blood pressure (BP) and heart rate (HR) in mild hypertensive subjects.
Thirty-seven mild hypertensive patients after a 2-week placebo period were randomized to bromazepam 3 mg, propranolol 40 mg, bromazepam 3 mg plus propranolol 40 mg or placebo for 2 weeks according to a double-blind, double dummy, cross-over design. After each treatment period, 24-h BP and HR ambulatory monitoring was performed by using a non-invasive device.
Ambulatory monitoring showed that during night-time SBP and DBP values were unaffected by bromazepam as compared to placebo, whereas SBP was significantly reduced by propranolol both when taken alone and in combination with bromazepam. HR nocturnal values were significantly reduced by propranolol, whereas they were significantly increased by bromazepan both when taken alone (+11.5%, p < 0.05 vs. placebo) and in combination with propranolol (+12.8%, p < 0.05 vs. propranolol). No significant difference in day-time values of SBP, DBP and HR was observed among the 4 treatment groups.
In mild hypertensive patients, evening consumption of bromazepam for a 2-week period did not affect BP, while it increased nocturnal HR. Such an increase was observed both when bromazepam was taken alone and in combination with propranolol, which suggests that it depends on a bromazepam mediated decrease in vagal tone. Whatever the mechanism, the HR nocturnal increase might be of clinical relevance, due to the role of high HR as cardiovascular risk factor, particularly in already at risk hypertensive subjects.
评估慢性晚间口服溴马唑仑单独或与普萘洛尔联合应用对轻中度高血压患者的动态血压(BP)和心率(HR)的影响。
37 例轻中度高血压患者在 2 周安慰剂期后,根据双盲、双模拟、交叉设计随机分为溴马唑仑 3mg、普萘洛尔 40mg、溴马唑仑 3mg 加普萘洛尔 40mg 或安慰剂治疗 2 周。在每个治疗期后,通过无创设备进行 24 小时 BP 和 HR 动态监测。
动态监测显示,与安慰剂相比,夜间 SBP 和 DBP 值不受溴马唑仑影响,而普萘洛尔单独和联合应用均显著降低 SBP。夜间 HR 值显著降低,而溴马唑仑单独和联合应用均显著增加(分别增加 11.5%,p<0.05 与安慰剂相比;增加 12.8%,p<0.05 与普萘洛尔相比)。4 种治疗组在白天 SBP、DBP 和 HR 值方面无显著差异。
在轻中度高血压患者中,溴马唑仑晚间连续服用 2 周不会影响血压,但会增加夜间 HR。这种增加既出现在溴马唑仑单独使用时,也出现在与普萘洛尔联合使用时,这表明它取决于溴马唑仑介导的迷走神经张力降低。无论机制如何,由于高 HR 作为心血管风险因素的作用,夜间 HR 增加可能具有临床相关性,特别是在已经存在风险的高血压患者中。